XOMA (XOMA)
(Delayed Data from NSDQ)
$24.78 USD
-0.66 (-2.59%)
Updated May 3, 2024 04:00 PM ET
After-Market: $25.10 +0.32 (1.29%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
XOMA Corporation [XOMA]
Reports for Purchase
Showing records 121 - 140 ( 328 total )
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
August and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
June and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financial Update: Cash Covers Two Proof-of-Concept Data Sets for Hyperinsulinism in 2016; Reiterate OUTPERFORM and $3 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
May and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
April and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q4/FY15 Update; POC Data for XOMA 358 in Congenital Hyperinsulinism Up Next; Reiterate OUTPERFORM but Reducing PT to $3 on Termination of PG Program
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
March and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
February and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - January and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Licensed XMetA for Diabetes to Novo Nordisk; Reiterate OUTPERFORM and $6 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Dropping Coverage
Provider: Roth Capital Partners, Inc.
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials; Xoma Completes Transformation into Endocrine Focused Company With Sale of Legacy Assets; Reiterate OUTPERFORM and $6 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
November and Remaining 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 2This report contains brief updates on the following: DYAX, ANAC, IRWD, ECYT, FATE, XNCR, RGLS, MGNX, FCSC, SNSS, INFI, MDVN, RPTP, SRPT, XOMA, AGTC, EPZM, BLUE, PTCT, CATB, EPRS, ABUS, ICPT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Phase 2 Trial of XOMA 358 in Congenital Hyperinsulinism Initiated; Reiterate OUTPERFORM and $6 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
October and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L